1-14 | As Liberia today celebrates 42 days without any new Ebola infections - effectively marking the end of the Ebola outbreak in West Africa, Médecins Sans Frontières (MSF) calls on the global health community to draw on lessons learnt in order to be better prepared for future similar outbreaks. MSF is also continuing its Ebola activities in Liberia, Sierra Leone and Guinea through running support clinics for Ebola survivors. “Today is a day of celebration and relief that this outbreak is finally over“ says Joanne Liu, MSF’s International President.
1-14 | As Liberia today celebrates 42 days without any new Ebola infections - effectively marking the end of the Ebola outbreak in West Africa, Médecins Sans Frontières (MSF) calls on the global health community to draw on lessons learnt in order to be better prepared for future similar outbreaks. MSF is also continuing its Ebola activities in Liberia, Sierra Leone and Guinea through running support clinics for Ebola survivors. “Today is a day of celebration and relief that this outbreak is finally over“ says Joanne Liu, MSF’s International President.
1-14 | As Liberia today celebrates 42 days without any new Ebola infections - effectively marking the end of the Ebola outbreak in West Africa, Médecins Sans Frontières (MSF) calls on the global health community to draw on lessons learnt in order to be better prepared for future similar outbreaks. MSF is also continuing its Ebola activities in Liberia, Sierra Leone and Guinea through running support clinics for Ebola survivors. “Today is a day of celebration and relief that this outbreak is finally over“ says Joanne Liu, MSF’s International President.
1-7 | A malaria drug may have reduced risk of dying among a group of Ebola patients in Liberia during the height of the outbreak in 2014, according to a retrospective study published by Doctors Without Borders/Médecins Sans Frontières (MSF) and its research arm Epicentre, in the New England Journal of Medicine Thursday (7 January). The study found that Ebola patients who were prescribed an antimalarial drug, artesunate-amodiaquine (ASAQ), had a 31 percent lower risk of dying than those who were prescribed the standard first-line antimalarial medicine, artemether-lume
1-7 | A malaria drug may have reduced risk of dying among a group of Ebola patients in Liberia during the height of the outbreak in 2014, according to a retrospective study published by Doctors Without Borders/Médecins Sans Frontières (MSF) and its research arm Epicentre, in the New England Journal of Medicine Thursday (7 January). The study found that Ebola patients who were prescribed an antimalarial drug, artesunate-amodiaquine (ASAQ), had a 31 percent lower risk of dying than those who were prescribed the standard first-line antimalarial medicine, artemether-lume